Insight Molecular Diagnostics
IMDX
33 hedge funds and large institutions have $22.5M invested in Insight Molecular Diagnostics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 2 closing their positions.
31,017% more capital inflows, than outflows
Capital inflows: $4.24M | Capital outflows: $13.6K
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
3% more funds holding
Funds holding: 32 → 33 (+1)
1.97% more ownership
Funds ownership: 10.89% → 12.86% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadwood Capital
New York
|
+$2.45M |
| 2 |
AG
Artal Group
Luxembourg
|
+$496K |
| 3 |
BlackRock
New York
|
+$471K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
+$260K |
| 5 |
Goldman Sachs
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Elgethun Capital Management
Sioux Falls,
South Dakota
|
-$5K |
| 2 |
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.46K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.16K |
IMDX Hedge Fund Activity: Q1 2017 in Review
33 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2017, worth a combined $22.5M — up 2% from $22M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMDX positions and 2 closed out — a net gain of 5 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $2.45M. The largest seller was Elgethun Capital Management, exiting entirely with an estimated $5K sold.
- 33 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2017, up from 32 in Q4 2016.
- Funds reported $22.5M of Insight Molecular Diagnostics stock for Q1 2017, up 2% quarter-over-quarter.
- 7 funds opened new Insight Molecular Diagnostics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2017 was Broadwood Capital, an estimated $2.45M added.
- The largest Insight Molecular Diagnostics seller in Q1 2017 was Elgethun Capital Management, an estimated $5K sold.
Based on aggregated 13F filings for Q1 2017.